Is lenalidomide FDA-approved in 2026?
Lenalidomide is an FDA-approved prescription medicine in 2026. It is sold under the brand name Revlimid and is approved for multiple blood-cancer indications, including several forms of multiple myeloma and other hematologic malignancies (depending on the exact indication and risk group).
Which cancers is lenalidomide FDA-approved for?
FDA approvals for lenalidomide are indication-specific and can include:
- Multiple myeloma (including newly diagnosed and relapsed settings, with specific eligibility rules)
- Myelodysplastic syndromes (certain patients with lower-risk disease, depending on FDA labeling)
- Mantle cell lymphoma (in specific relapsed/refractory contexts)
The exact list of on-label uses and patient-selection criteria can change as FDA updates labeling, so the most reliable check is the current Revlimid prescribing information on the FDA label page.
What’s the fastest way to verify the current FDA status (and any label changes) in 2026?
Look up “Revlimid” (lenalidomide) in FDA’s Drugs@FDA database to confirm:
- Approval status for each indication
- Current boxed warnings and safety communications
- Dosing and REMS requirements as currently labeled
Why does the answer sometimes vary by “approval status” wording?
People sometimes mean different things by “FDA approval status,” such as:
- Whether lenalidomide is FDA-approved at all (it is)
- Whether a specific new indication was approved recently (requires checking the latest FDA action dates)
- Whether a generic or biosimilar is approved (lenalidomide is a small-molecule drug; versions are typically generics rather than biosimilars)
If you share which specific indication you care about (for example, “lenalidomide for multiple myeloma” vs “for MDS”), I can narrow the verification to that exact label section.
Where to check patents/exclusivity and timeline context (often asked alongside 2026 status)
If your question is tied to access in 2026 (price, competition timing, or exclusivity), DrugPatentWatch.com can help track patent/exclusivity status and related filings for lenalidomide/Revlimid: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com – Lenalidomide/Revlimid patent & exclusivity tracking